Synthetic Cannabinoid Adulterants Are Reentering the Clinical Picture as Cannabis Use Expands
The expansion of medical and recreational cannabis has not simplified cannabinoid exposure. It has widened the clinical field in which synthetic cannabinoid receptor agonists and semi-synthetic cannabinoids can appear, sometimes hidden inside substances patients believe are familiar and relatively predictable. A 2025 review in Neuroscience and Biobehavioral Reviews argues that this convergence is creating a second wave of poisonings, one shaped by adulteration, inconsistent potency, and a much less stable toxicologic profile than plant-derived cannabis alone.
A single exposure can no longer be assumed to reflect a single product.
SCRAs behave differently from natural cannabinoids because they act as potent full agonists at cannabinoid receptors rather than the partial agonism associated with delta-9-tetrahydrocannabinol. In practical terms, that receptor pharmacology can translate into a broader and less predictable toxic burden. Patients may present with agitation, psychosis, autonomic instability, or other features of cannabinoid toxicity that are difficult to reconcile with the history they provide or the product they describe. When adulterants are mixed into cannabis or opioids, the result is not just contamination; it is a new exposure pattern with implications for emergency care, toxicology, addiction medicine, and public health surveillance.
Full Agonism, Uncertain Dose, and a More Unstable Toxicology
The review places emphasis on the biological reasons these exposures are so difficult to manage. Full agonist activity at cannabinoid receptors can produce more intense and less forgiving effects than the partial receptor activation associated with natural cannabis. When the adulterant is embedded in a recreational substance, the clinician loses two anchors at once: accurate dose estimation and confidence in the expected syndrome. That combination increases the risk of misclassification at triage, delayed recognition of severe intoxication, and treatment plans that underestimate the physiologic volatility of the exposure.
Semi-synthetic cannabinoids complicate the picture further by blurring the line between natural and manufactured cannabinoid products. Legal access to cannabis has not eliminated demand for novel psychoactive compounds, and the market has responded with substances that are chemically and clinically harder to track. In that setting, the bedside problem is no longer simply whether a patient used cannabis. The deeper question is whether the exposure included a more potent agonist, an adulterant, or a mixture of several agents with overlapping neuropsychiatric effects.
Diagnosis Depends on History, Exam, and Selective Laboratory Testing
Clinical recognition begins with basic medicine rather than exotic testing. The review stresses the value of a careful patient history, a focused physical examination, and judicious laboratory evaluation when cannabinoid toxicity is suspected. That approach is especially important because routine histories often miss the key exposure detail: the product may have been laced, mislabeled, or intentionally modified. Patients may report cannabis use while unknowingly carrying a far more toxic synthetic compound in the same product stream.
Physical findings matter because the syndrome can be protean. A patient with cannabinoid-related toxicity may not fit a narrow textbook pattern, and the presence of co-ingestants can obscure the picture even further. Laboratory tests can support evaluation, but they do not replace the bedside assessment. In the context of adulteration, toxicology results are most useful when they inform severity assessment, identify complications, and help differentiate cannabinoid toxicity from other acute neurologic or psychiatric emergencies.
Prior Drug Epidemics Offer a Clear Warning for Clinicians and Policymakers
The review draws parallels with prior drug epidemics, and the comparison is clinically apt. Each wave of novel substance exposure has followed a familiar sequence: initial underrecognition, inconsistent identification at the bedside, slow adaptation of public health messaging, and eventual pressure for better surveillance and treatment guidance. Synthetic cannabinoids fit that pattern closely. Their resurgence as adulterants shows how quickly a regulated or partially regulated market can be complicated by products that evade standard expectations about purity and potency.
The danger is amplified by drug interactions. When SCRAs are introduced into cannabis or opioid supplies, clinicians may face mixed presentations that do not map cleanly onto one toxidrome. Respiratory depression, agitation, delirium, seizure risk, cardiovascular instability, and psychiatric manifestations can coexist or evolve rapidly. This is not a theoretical concern. It changes how clinicians think about observation periods, escalation of care, and the threshold for expanded diagnostic workup.
Clinical Preparedness Now Requires a Wider Toxicology Lens
The article frames this resurgence as a call for preparedness, and the message reaches beyond toxicologists. Emergency physicians, psychiatrists, primary care clinicians, addiction specialists, and hospitalists are all likely to encounter patients affected by adulterated cannabinoid products. Recognizing the problem early can prevent diagnostic anchoring, especially when a presentation appears to be “just cannabis” in a patient with anxiety, altered mental status, or unusual neurologic findings.
Supportive care remains central, but supportive care begins with recognizing what is actually in front of the clinician. In a patient whose cannabis exposure is complicated by an SCRA adulterant, the severity of symptoms may be disproportionate to the history. That mismatch should trigger broader suspicion, closer monitoring, and more deliberate documentation of the suspected exposure pathway.
Quality Control, Public Awareness, and Evidence-Based Guidance Are Still Missing
The review ends with a direct policy message: robust quality control measures, stronger public awareness campaigns, and evidence-based clinical guidelines are needed to reduce harm from both intentional and unintentional synthetic cannabinoid exposure. Those needs are especially urgent in an era when legalization can create a false sense of safety around cannabinoid products. Legal status does not guarantee product purity, and it does not prevent the circulation of synthetic adulterants in illicit or semi-legal markets.
For clinicians, the next step is not abstract vigilance. It is disciplined suspicion. Cannabinoid toxicity in the current era may reflect a much more complex exposure than the label suggests, and the difference can determine whether a patient is observed briefly, admitted for complication management, or treated for a syndrome that was never obvious from the initial history alone. The review’s central warning is grounded in pharmacology and bedside reality: the next cannabinoid presentation may not be what it seems, and the clinical response has to account for that uncertainty.